AIM is expected to report earnings to rise 100.00% to -5 cents per share on November 15
Q3'24
Est.
$-0.06
Q2'24
Beat
by $0.09
Q1'24
Est.
$-0.12
Q4'23
Missed
by $0.14
Q3'23
Missed
by $0.05
The last earnings report on August 16 showed earnings per share of -2 cents, beating the estimate of -11 cents. With 10.60K shares outstanding, the current market capitalization sits at 15.43M.
a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders